Innovent
信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

RE-DESIGNATION OF DIRECTOR AND CHANGE OF AUTHORIZED REPRESENTATIVE

RE-DESIGNATION OF DIRECTOR

The board (the "**Board**") of Directors (the "**Directors**", each a "**Director**") of Innovent Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that with effect from September 1, 2026, Mr. Ronald Hao Xi Ede ("**Mr. Ede**") will be re-designated from an executive Director to a non-executive Director as he wishes to retire from full-time employment and devote more time to his family. Mr. Ede has also tendered his resignation as the authorized representative (the "**Authorized Representative**") under Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Mr. Ede will remain as a member of the strategy committee of the Board (the "**Strategy Committee**"). Mr. Ede has confirmed that there are no matters relating to his re-designation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The biographical details of Mr. Ede are set out below:

Mr. Ronald Hao Xi Ede

Mr. Ronald Hao Xi Ede, aged 67, has been an executive Director since October 31, 2018. Mr. Ede has been and will remain as a member of the Strategy Committee, and the Managing Partner of the Company's investment funds. Mr. Ede served as the Chief Financial Officer of the Company from August 2017 to February 2024 and has made significant contributions to the Company's strategy planning, corporate governance, financial management and business development. Prior to joining the Group, between 2011 and 2016, Mr. Ede was the chief financial officer of Biosensors International Ltd. Between 2009 and 2011, Mr. Ede was the chief financial officer of Mindray Medical International Limited. Mr. Ede is a fellow member of the Institute of Singapore Chartered Accountants and an A-Share independent director certified by the Shenzhen Stock Exchange. Mr. Ede received his bachelor of business administration degree from the University of Hawaii in December 1984 and a master of business administration degree from the University of Washington in December 1988. Outside of the Group, Mr. Ede has held directorship in Dawnrays Pharmaceutical (Holdings) Limited (a company listed on the Main Board of the Stock Exchange with stock code: 2348) as a non-executive director since 2015. In 2017, Mr. Ede was re-designated as an independent non-executive director.

Mr. Ede has entered into a new letter of appointment with the Company for a term of three years commencing on September 1, 2026 and continuing thereafter until terminated by either party by giving at least three months' notice in writing. Mr. Ede is subject to retirement by rotation and re-election at the forthcoming annual general meeting in accordance with the memorandum and articles of association of the Company and the Corporate Governance Code as set out in Appendix C1 to the Listing Rules. Pursuant to the letter of appointment, Mr. Ede shall be entitled to receive a director's fees of RMB400,000 per annum, which has been determined by the Board upon recommendation of the remuneration committee of the Company with reference to his experience and duties with the Company and prevailing market conditions.

With respect to Mr. Ede's biographical information, save as disclosed above, as at the date of this announcement, (i) Mr. Ede does not hold any other position in the Company or its subsidiaries; (ii) Mr. Ede does not hold any other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) Mr. Ede does not have any relationship with any Directors, senior management, substantial shareholders (as defined under the Listing Rules) or controlling shareholders (as defined under the Listing Rules) of the Company; and (iv) Mr. Ede does not possess any other professional qualifications.

Save as disclosed above, the Board is not aware of any other matters relating to the re-designation of Mr. Ede that need to be brought to the attention of the shareholders of the Company, nor is there any other information which is required to be disclosed by the Company pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

CHANGE OF AUTHORIZED REPRESENTATIVE

Mr. Ede has tendered his resignation as the Authorized Representative and Dr. De-Chao Michael Yu ("**Dr. Yu**") has been appointed as the Authorized Representative with effect from September 1, 2026.

The Board would like to extend a warm welcome to Mr. Ede and Dr. Yu on their respective new roles.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
August 25, 2026

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.